Community/Retail

GLP-1 receptor agonists significantly influence FDG-PET-CT scan interpretations, potentially leading to misdiagnosis in cancer detection.

Many factors lead to policy change and market viability, but none more than perceived need and desire to receive a service.

As one of the most prescribed medications worldwide, proton pump inhibitor use could serve as a bulwark against severe outcomes in hospitalized adults with COVID-19.

Pharmaceutical companies navigate FDA regulations and explore AI solutions to enhance compliance in drug advertising and enforcement.

Researchers explore continuous glucose monitors (CGMs) for early detection of insulin issues, aiming to prevent diabetes progression and improve screening methods.

New research confirms that calcium supplements do not increase dementia risk in older women, supporting their use for bone health without cognitive concerns.

Christian Ruff, MD, highlights pharmacists as essential clinical partners who help optimize drug selection, dosing, and safety for patients with complex needs.

Cagrilintide shows significant weight loss in adults with obesity, marking a breakthrough in obesity treatment with promising phase 3 trial results.

Vaccination with 23-valent pneumococcal polysaccharide vaccine did not reduce the rates of acute coronary syndrome and ischemic stroke in a randomized clinical trial.

Craig Beavers discusses recent developments in hypertension management and the clinical implications of the Bax Hypertension and KARDIA-3 trials with Shelby Tungate from the UNC Eshelman School of Pharmacy.

Recent research confirms that rheumatoid arthritis patients in remission can safely switch to the biosimilar infliximab-dyyb, offering a cost-effective treatment option.

William Van Decker, MD, discusses the key priorities of the upcoming ACC Legislative Conference, including telehealth, cardiovascular rehab, prior authorization reform, and the role of pharmacists in shaping patient-centered cardiovascular policy.

Johnson & Johnson presented new long-term data of icotrokinra from ICONIC-LEAD, along with data from ICONIC-ADVANCE indicating head-to-head superiority with standard-of-care deucravacitinib.

Datopotamab deruxtecan shows promise as a first-line treatment for metastatic triple-negative breast cancer, improving survival in nonimmunotherapy candidates.

Research highlights the effectiveness of the albuterol-budesonide combination for ensuring rapid relief and safety in patients with asthma.

Explore the evolving role of pharmacists in navigating FDA regulations and the impact of drug ads on patient care.

New results from the phase 3 HYPERION trial demonstrate reduced risks as early as the year following diagnosis of pulmonary arterial hypertension.

The approval is supported by findings from the INTEGUMENT-PED trial and the INTEGUMENT-OLE long-term extension study.

Martha Thorne discusses the operational, financial, and patient care challenges pharmacies face under the 340B rebate pilot and the need for advocacy, automation, and transparency to sustain access.

Recent research reveals that continuous glucose monitors (CGMs) may inaccurately overestimate blood sugar levels, potentially leading to unnecessary dietary changes for healthy individuals.

Pulmonary fibrosis was observed in many patients with severe COVID-19 in a retrospective cohort study, indicating the need for more effective care and prevention.

For American Pharmacists Month, see how recent instances of conflicting medical advice show the importance of pharmacists as trustworthy health care professionals.

A phase 3 study shows SYSA1902, a biosimilar to Stelara, is clinically equivalent for treating moderate to severe plaque psoriasis.

This is the second generic version of mifepristone to be approved by the FDA.

Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.

Discover how pharmacists play a crucial role in the OUD treatment process with buprenorphine, enhancing patient care and recovery outcomes.